Coffee Chat: Best practice in managing the unique needs of non-viral HCC
Important information
The following feature is intended for healthcare professionals only. Please tick the box below to confirm that you are a healthcare professional.
This Coffee Chat has been initiated & funded by Eisai Europe Ltd
Discover the latest evidence and clinical experience on best practices for managing the unique needs of non-viral hepatocellular carcinoma (HCC) patients.
Register for our exclusive Coffee Chat focusing on non-viral HCC. This informal discussion, filmed at the ESMO 2023 Congress (20–24 October 2023, Madrid, Spain) explores the current management of people with non-viral HCC as well as the challenges associated with the clinical management of the disease.
Hosted by Rachel Jenkins (Oncology Central), the conversation features two experts who have a passion for advancing clinical practice for HCC patients: Andrea Casadei Gardini (Università Vita-Salute San Raffaele, Milan, Italy) and David J Pinato (Imperial College, London).
What will you learn?
- What is the current pathway for managing non-viral HCC?
- How does the prognosis of people with non-viral HCC compare to viral causes of HCC?
- What challenges do we face in the management of people with non-viral HCC?
- Do people with non-viral HCC have unique needs compared to people with viral HCC?
- What can we expect in the next 5-10 years?
Who this may interest?
- Clinical Oncologists
- Translational researchers
- Surgeons
Speakers
Dr David J Pinato
Consultant Medical Oncologist & Clinician Scientist
Imperial College London (UK)
Prof Andrea Casadei Gardini
Associate Professor of Medical Oncology
University Vita-Salute San Raffaele (Milan, Italy)
Initiated & funded by Eisai Europe Ltd